接受姑息放疗与PD-1免疫检查点抑制剂治疗的转移性癌症患者淋巴细胞减少的剂量学建模
本研究纳入55例接受帕博利珠单抗或纳武利尤单抗并接受颅外姑息放疗的转移性肺癌、黑色素瘤或肾细胞癌患者,共80个放疗疗程。全身、骨骼和大血管的V15剂量及循环淋巴细胞建模剂量与绝对淋巴细胞计数最低值负相关,且与≥3级淋巴细胞减少相关。
要点
- 全身、骨骼和大血管V15剂量与绝对淋巴细胞计数最低值负相关。
- 大血管V15、骨骼V15、全身V15及建模淋巴细胞剂量与≥3级淋巴细胞减少相关。
- 其他器官剂量与绝对淋巴细胞计数最低值无显著相关性。
核心结论
- 姑息放疗期间全身、骨骼和大血管的放疗剂量及循环淋巴细胞建模剂量与接受抗PD-1免疫检查点抑制剂患者的淋巴细胞减少相关。
- 这些发现可能为该场景下的未来放疗计划提供参考。
研究设计与样本
- 研究纳入55例接受帕博利珠单抗或纳武利尤单抗并接受颅外部位姑息放疗的转移性肺癌、黑色素瘤或肾细胞癌患者,共分析80个姑息放疗疗程。
- 大多数(94%)疗程采用三维适形放疗。
- 记录放疗前及放疗后6周内绝对淋巴细胞计数最低值,从剂量体积直方图提取剂量学因素,并通过模拟放疗期间主要器官中血液颗粒时空分布的全身血流模型对循环淋巴细胞剂量进行建模。
主要发现
- 全身、骨骼和大血管剂量与绝对淋巴细胞计数最低值负相关,最强相关性见于V15(rs分别为-0.38、-0.43和-0.37,P分别为.0004、.0001和.0008)。
- 其他器官剂量与绝对淋巴细胞计数最低值无显著相关性。
- 循环淋巴细胞建模剂量与绝对淋巴细胞计数最低值及绝对淋巴细胞计数变化百分比负相关(D2%的rs分别为-0.31和-0.44,P分别为.005和.0001)。
- ≥3级淋巴细胞减少与大血管V15(OR 1.16,95%CI 1.07-1.26,P<.001)、骨骼V15(OR 1.04,95%CI 1.01-1.08,P=.03)、全身V15(OR 1.003,95%CI 1.001-1.006,P=.008)及建模淋巴细胞剂量(OR 1.45,95%CI 1.16-1.82,P<.001)相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy (RT)-associated lymphopenia may adversely affect treatment outcomes, particularly in the era of immunotherapy. We sought to determine dosimetric factors correlated with lymphopenia after palliative RT in a cohort of patients with advanced cancer treated with anti-PD-1 immune checkpoint inhibitors. METHODS AND MATERIALS: We included patients with metastatic lung cancer, melanoma, or renal cell carcinoma who were treated with either pembrolizumab or nivolumab and received palliative RT to an extracranial site. Baseline and nadir absolute lymphocyte counts (ALCs) within 6 weeks of RT were recorded. Dosimetric factors were extracted from the corresponding dose-volume histograms and also used to model the dose to circulating lymphocytes via a whole-body blood flow model that simulates the spatiotemporal distribution of blood particles in major organs during RT. RESULTS: We analyzed 55 patients who underwent 80 total courses of palliative RT; most (94%) were treated with 3-dimensional conformal RT. Doses to the whole body, bone, and large blood vessels (LBVs) were negatively correlated with the ALC nadir, with the strongest correlations seen at V15 (rs, -0.38, -0.43, and -0.37, and P = .0004, .0001, and .0008, respectively). Doses to other organs were not significantly correlated with the ALC nadir. The modeled dose to circulating lymphocytes was also negatively correlated with the ALC nadir and percent ALC change (for D2%, rs, -0.31 and -0.44, and P = .005 and .0001, respectively). Grade ≥3 lymphopenia was associated with LBV V15 (odds ratio [OR], 1.16; 95% CI, 1.07-1.26; P < .001), bone V15 (OR, 1.04; 95% CI, 1.01-1.08; P = .03), body V15 (OR, 1.003; 95% CI, 1.001-1.006; P = .008), and modeled lymphocyte dose (OR, 1.45; 95% CI, 1.16-1.82; P < .001). CONCLUSIONS: The RT dose to the whole body, bone, and LBVs and the modeled dose to circulating lymphocytes were correlated with lymphopenia in patients treated with palliative RT and anti-PD-1 immune checkpoint inhibitors. These findings may inform future radiation planning in this setting.
引用
- Qian JM, Akama-Garren E, Shin J, et al. Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors. Adv Radiat Oncol. 2021. PMID: 35097241. doi:10.1016/j.adro.2021.100880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。